Latest Insider Transactions at Nurix Therapeutics, Inc. (NRIX)
This section provides a real-time view of insider transactions for Nurix Therapeutics, Inc. (NRIX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Nurix Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Nurix Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 30
2022
|
Stefani Wolff EVP and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
962
+37.64%
|
-
|
|
Jul 30
2022
|
Hans Van Houte Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,886
+3.78%
|
-
|
|
Jul 30
2022
|
Gwenn Hansen Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,207
+13.61%
|
-
|
|
May 31
2022
|
Hans Van Houte Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
68,333
+49.21%
|
$0
$0.84 P/Share
|
|
May 02
2022
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
660
-16.24%
|
$7,260
$11.75 P/Share
|
|
May 02
2022
|
Hans Van Houte Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
697
-24.15%
|
$7,667
$11.75 P/Share
|
|
May 02
2022
|
Stefani Wolff EVP and COO |
SELL
Open market or private sale
|
Direct |
330
-34.3%
|
$3,630
$11.75 P/Share
|
|
May 02
2022
|
Gwenn Hansen Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,098
-6.02%
|
$12,078
$11.75 P/Share
|
|
Apr 30
2022
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,924
+32.14%
|
-
|
|
Apr 30
2022
|
Hans Van Houte Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,886
+50.0%
|
-
|
|
Apr 30
2022
|
Stefani Wolff EVP and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
962
+50.0%
|
-
|
|
Apr 30
2022
|
Gwenn Hansen Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,206
+14.94%
|
-
|
|
Jan 10
2022
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,200
-48.27%
|
$32,400
$27.14 P/Share
|
|
Jan 10
2022
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,200
+32.56%
|
$1,200
$1.86 P/Share
|
|
Jan 03
2022
|
Gwenn Hansen Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,828
-11.41%
|
$51,184
$28.96 P/Share
|
|
Jan 03
2022
|
Gwenn Hansen Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,828
+5.42%
|
$14,624
$8.42 P/Share
|
|
Dec 10
2021
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,200
-48.27%
|
$34,800
$29.04 P/Share
|
|
Dec 10
2021
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,200
+32.56%
|
$1,200
$1.86 P/Share
|
|
Dec 01
2021
|
Gwenn Hansen Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
400
-2.74%
|
$11,600
$29.13 P/Share
|
|
Dec 01
2021
|
Gwenn Hansen Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
400
+2.67%
|
$2,800
$7.26 P/Share
|
|
Nov 10
2021
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,200
-48.27%
|
$38,400
$32.38 P/Share
|
|
Nov 10
2021
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,200
+32.56%
|
$1,200
$1.86 P/Share
|
|
Nov 01
2021
|
Gwenn Hansen Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
400
-2.74%
|
$13,200
$33.24 P/Share
|
|
Nov 01
2021
|
Gwenn Hansen Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
400
+2.67%
|
$2,800
$7.26 P/Share
|
|
Oct 27
2021
|
Gwenn Hansen Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
400
-2.74%
|
$14,000
$35.0 P/Share
|
|
Oct 27
2021
|
Gwenn Hansen Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
400
+2.67%
|
$2,800
$7.26 P/Share
|
|
Oct 27
2021
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
800
-38.35%
|
$28,000
$35.25 P/Share
|
|
Oct 27
2021
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
800
+27.72%
|
$800
$1.86 P/Share
|
|
Oct 11
2021
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,200
-48.27%
|
$32,400
$27.36 P/Share
|
|
Oct 11
2021
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,200
+32.56%
|
$1,200
$1.86 P/Share
|
|
Oct 01
2021
|
Gwenn Hansen Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
400
-2.74%
|
$11,600
$29.92 P/Share
|
|
Oct 01
2021
|
Gwenn Hansen Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
400
+2.67%
|
$2,800
$7.26 P/Share
|
|
Sep 10
2021
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,000
-26.33%
|
$70,000
$35.88 P/Share
|
|
Sep 10
2021
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+37.84%
|
$2,000
$1.86 P/Share
|
|
Sep 07
2021
|
Gwenn Hansen Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,600
-10.13%
|
$56,000
$35.0 P/Share
|
|
Sep 07
2021
|
Gwenn Hansen Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,600
+9.2%
|
$11,200
$7.26 P/Share
|
|
Sep 07
2021
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,200
-71.33%
|
$112,000
$35.25 P/Share
|
|
Sep 07
2021
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,200
+41.63%
|
$3,200
$1.86 P/Share
|
|
Sep 01
2021
|
Gwenn Hansen Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
400
-2.74%
|
$12,800
$32.34 P/Share
|
|
Sep 01
2021
|
Gwenn Hansen Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
400
+2.67%
|
$2,800
$7.26 P/Share
|
|
Aug 10
2021
|
Pierre Beaurang Chief Business Officer |
SELL
Open market or private sale
|
Direct |
7,500
-38.89%
|
$217,500
$29.97 P/Share
|
|
Aug 10
2021
|
Pierre Beaurang Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+38.8%
|
$7,500
$1.11 P/Share
|
|
Aug 10
2021
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,200
-59.85%
|
$34,800
$29.87 P/Share
|
|
Aug 10
2021
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,200
+37.44%
|
$1,200
$1.86 P/Share
|
|
Aug 02
2021
|
Gwenn Hansen Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
400
-2.82%
|
$12,400
$31.21 P/Share
|
|
Aug 02
2021
|
Gwenn Hansen Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
400
+2.74%
|
$2,800
$7.26 P/Share
|
|
Jul 20
2021
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,200
-59.85%
|
$32,400
$27.0 P/Share
|
|
Jul 20
2021
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,200
+37.44%
|
$1,200
$1.86 P/Share
|
|
Jul 12
2021
|
Pierre Beaurang Chief Business Officer |
SELL
Open market or private sale
|
Direct |
7,500
-34.24%
|
$180,000
$24.3 P/Share
|
|
Jul 12
2021
|
Pierre Beaurang Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+38.8%
|
$7,500
$1.11 P/Share
|